KEYTRUDA 25 mg/mL concentrate for solution for infusion, SUNITINIB , AXITINIB
MK-3475-426
Phase 3 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, SUNITINIB , AXITINIB for Metastatic renal cell carcinoma is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Metastatic renal cell carcinoma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active